COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development.
Exp Biol Med (Maywood)
; 246(13): 1533-1540, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-1148197
ABSTRACT
Novel 2019 coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) and coronavirus disease 2019 (COVID-19), the respiratory syndrome it causes, have shaken the world to its core by infecting and claiming the lives of many people since originating in December 2019 in Wuhan, China. World Health Organization and several states have declared a pandemic situation and state of emergency, respectively. As there is no treatment for COVID-19, several research institutes and pharmaceutical companies are racing to find a cure. Advances in computational approaches have allowed the screening of massive antiviral compound libraries to identify those that may potentially work against SARS-CoV-2. Antiviral agents developed in the past to combat other viruses are being repurposed. At the same time, new vaccine candidates are being developed and tested in preclinical/clinical settings. This review provides a detailed overview of select repurposed drugs, their mechanism of action, associated toxicities, and major clinical trials involving these agents.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Enzyme Inhibitors
/
Drug Development
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Exp Biol Med (Maywood)
Journal subject:
Biology
/
Physiology
/
Medicine
Year:
2021
Document Type:
Article
Affiliation country:
1535370221999989
Similar
MEDLINE
...
LILACS
LIS